BioWorld

July 13, 2004

View Archived Issues

Genentech, Phenomix Enter Immune Disorder Target Deal

Genentech Inc. signed a multiyear collaboration with Phenomix Corp. to identify and prioritize drug targets for immune disorders. (BioWorld Today) Read More

Incyte's Reverset Phase II Positive In Treatment-Experienced Patients

Read More

Microscience Pulls IPO; Firms In UK Struggle With Valuations

Read More

Other News To Note

Read More

Appointments And Advancements

Read More